Login to Client Zone

You are here: News & Resources > Market News > GSK offer for Human Genome Sciences anti-trust clearance

GSK offer for Human Genome Sciences anti-trust clearance

GlaxoSmithKline's tender offer for Human Genome Sciences has been cleared under US anti-trust laws with the expiration of the Hart-Scott-Rodino waiting period.

GSK;s offer of $13.00 per share represents a premium of 81% to HGS's closing share price of US$7.17 on 18 April 2012, the last trading day before HGS publicly disclosed GSK's private offer.

At 2:05pm: (LON:GSK) GlaxoSmithKline share price was -15.75p at 1422.25p

Story provided by StockMarketWire.com

01/06/2012

When investing in stockmarkets there is the risk of loss to investors' capital and income. Click on "Risk Warning" below for further details.

Hargreave Hale Limited ("Hargreave Hale") is authorised and regulated by the Financial Services Authority (No. 209741).
and is a member of the London Stock Exchange, the Plus Market and APCIMS. The company is incorporated in England and Wales, Company No. 3146580.
The registered office is at 9-11 Neptune Court, Hallam Way, Blackpool, FY4 5LZ.

Risk Warning| Terms and Conditions| Disclaimer| Policy Statements| Privacy Policy| Frequently Asked Questions| Site Map

Copyright © All rights reserved Hargreave Hale Limited | Professional Website Design by GPMD